BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 33720084)

  • 1. Immunohistochemistry and Next-generation Sequencing Are Complementary Tests in Identifying PTEN Abnormality in Endometrial Carcinoma Biopsies.
    Wang L; Piskorz A; Bosse T; Jimenez-Linan M; Rous B; Gilks CB; Brenton JD; Singh N; Köbel M
    Int J Gynecol Pathol; 2022 Jan; 41(1):12-19. PubMed ID: 33720084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing.
    Djordjevic B; Hennessy BT; Li J; Barkoh BA; Luthra R; Mills GB; Broaddus RR
    Mod Pathol; 2012 May; 25(5):699-708. PubMed ID: 22301702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between PTEN, DNA mismatch repair, and tumor histotype in endometrial carcinoma: retained positive expression of PTEN preferentially identifies sporadic non-endometrioid carcinomas.
    Djordjevic B; Barkoh BA; Luthra R; Broaddus RR
    Mod Pathol; 2013 Oct; 26(10):1401-12. PubMed ID: 23599155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies.
    Singh N; Piskorz AM; Bosse T; Jimenez-Linan M; Rous B; Brenton JD; Gilks CB; Köbel M
    J Pathol; 2020 Mar; 250(3):336-345. PubMed ID: 31829441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histotype-genotype correlation in 36 high-grade endometrial carcinomas.
    Hoang LN; McConechy MK; Köbel M; Han G; Rouzbahman M; Davidson B; Irving J; Ali RH; Leung S; McAlpine JN; Oliva E; Nucci MR; Soslow RA; Huntsman DG; Gilks CB; Lee CH
    Am J Surg Pathol; 2013 Sep; 37(9):1421-32. PubMed ID: 24076778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Many Uses of p53 Immunohistochemistry in Gynecological Pathology: Proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual9 Meeting.
    Köbel M; Kang EY
    Int J Gynecol Pathol; 2021 Jan; 40(1):32-40. PubMed ID: 33290354
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Immunohistochemistry to Distinguish Grade 3 Endometrioid Carcinoma and Uterine Serous Carcinoma.
    Zaidi A; Gupta P; Gupta N; Rajwanshi A; Rai B; Gainder S
    Appl Immunohistochem Mol Morphol; 2020 Jan; 28(1):42-48. PubMed ID: 31815745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of endometrial carcinoma on biopsy as a predictor of final surgical pathology: Are we doing it right? A completed audit cycle and recommendations.
    Jassar A; Hemali N; Bhatnagar A
    Indian J Pathol Microbiol; 2024; 67(1):68-73. PubMed ID: 38358191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients.
    Westin SN; Ju Z; Broaddus RR; Krakstad C; Li J; Pal N; Lu KH; Coleman RL; Hennessy BT; Klempner SJ; Werner HM; Salvesen HB; Cantley LC; Mills GB; Myers AP
    Mol Oncol; 2015 Oct; 9(8):1694-703. PubMed ID: 26045339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of PTEN in endometrial liquid-based cytology.
    Di Lorito A; Zappacosta R; Capanna S; Gatta DM; Rosini S; Schmitt FC
    Acta Cytol; 2014; 58(5):495-500. PubMed ID: 25358681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible.
    Garg K; Broaddus RR; Soslow RA; Urbauer DL; Levine DA; Djordjevic B
    Int J Gynecol Pathol; 2012 Jan; 31(1):48-56. PubMed ID: 22123723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Immunohistochemical expression of PTEN antigen: a new tool for diagnosis of early endometrial neoplasia].
    Taranger-Charpin C; Carpentier S; Dales JP; Garcia S; Djemli A; Andrac L; Lavaut MN; Sferlazzo K; Boubli L
    Bull Acad Natl Med; 2004; 188(3):415-27; discussion 427-9. PubMed ID: 15584653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PTEN and p53 abnormalities are indicative and predictive factors for endometrial carcinoma.
    Inaba F; Kawamata H; Teramoto T; Fukasawa I; Inaba N; Fujimori T
    Oncol Rep; 2005 Jan; 13(1):17-24. PubMed ID: 15583796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27.
    An HJ; Lee YH; Cho NH; Shim JY; Kim JY; Lee C; Kim SJ
    Histopathology; 2002 Nov; 41(5):437-45. PubMed ID: 12405911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles.
    McConechy MK; Ding J; Senz J; Yang W; Melnyk N; Tone AA; Prentice LM; Wiegand KC; McAlpine JN; Shah SP; Lee CH; Goodfellow PJ; Gilks CB; Huntsman DG
    Mod Pathol; 2014 Jan; 27(1):128-34. PubMed ID: 23765252
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological and molecular characteristics of endometrial neuroendocrine carcinomas reveal preexisting endometrial carcinoma origin.
    Ono K; Kasajima R; Katayama K; Miyagi Y; Yokose T
    Pathol Int; 2021 Aug; 71(8):491-499. PubMed ID: 34015161
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment.
    Peiró G; Peiró FM; Ortiz-Martínez F; Planelles M; Sánchez-Tejada L; Alenda C; Ceballos S; Sánchez-Payá J; Laforga JB
    Hum Pathol; 2013 Feb; 44(2):218-25. PubMed ID: 22955108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma.
    Stelloo E; Nout RA; Naves LC; Ter Haar NT; Creutzberg CL; Smit VT; Bosse T
    Gynecol Oncol; 2014 May; 133(2):197-204. PubMed ID: 24556061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression.
    Huang HN; Lin MC; Tseng LH; Chiang YC; Lin LI; Lin YF; Huang HY; Kuo KT
    Histopathology; 2015 Mar; 66(4):517-28. PubMed ID: 25195947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations.
    Murali R; Davidson B; Fadare O; Carlson JA; Crum CP; Gilks CB; Irving JA; Malpica A; Matias-Guiu X; McCluggage WG; Mittal K; Oliva E; Parkash V; Rutgers JKL; Staats PN; Stewart CJR; Tornos C; Soslow RA
    Int J Gynecol Pathol; 2019 Jan; 38 Suppl 1(Iss 1 Suppl 1):S40-S63. PubMed ID: 30550483
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.